Silvia Juliana Serrano-Gómez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Silvia Juliana Serrano-Gómez has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Laura Rey-Vargas
Affiliations National Cancer Institute, Cancer Biology Research Group, Bogotá, D.C, Colombia, Doctoral Program in Biological Sciences, Pontificia Universidad Javeriana, Bogotá, D.C, Colombia
3 shared publications- Laura Rey-Vargas
Instituto Nacional de Cancerologia
3 shared publications María Carolina Sanabria-Salas
Cancer Biology Research Group, National Cancer Institute of Colombia, Bogotá, Colombia
3 shared publications- Alba Lucia Combita
Instituto Nacional de Cancerologia
2 shared publications - Carlos Alexander Huertas-Caro
Instituto Nacional de Cancerologia
2 shared publications - Diego Felipe Ballen
Instituto Nacional de Cancerologia
2 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 72-84
Epidemiología molecular: el papel del Atlas del Genoma del Cáncer a lo largo de la historia
Introducción: el Atlas del Genoma del Cáncer (TCGA) ha sido un proyecto colaborativo internacional y multiinstitucional diseñado para caracterizar de manera integral las alteraciones moleculares de tumores de alta relevancia clínica. Este trabajo resume sus principales aportes, así como las limitaciones y retos derivados de su implementación. Métodos: se realizó una búsqueda estructurada en PubMed, EMBASE y Web of Science sobre TCGA, incluyendo publicaciones relacionadas con sus resultados, metodología, limitaciones y repercusiones clínicas y traslacionales. Resultados: se identificaron 88 publicaciones relevantes. TCGA analizó más de 20.000 muestras correspondientes a 33 tipos tumorales, integrando datos genómicos, transcriptómicos, epigenómicos y proteómicos. Entre sus contribuciones más relevantes destacan: a) la redefinición de la clasificación tumoral mediante subtipos moleculares, b) la identificación de mutaciones y vías de señalización con impacto terapéutico, como IDH1 en gliomas y subtipos moleculares en cáncer de mama, endometrio y estómago, c) la validación de biomarcadores pronósticos y predictivos, y d) el desarrollo de bases de datos abiertas que impulsaron estudios traslacionales y ensayos clínicos tipo canasta. En 2018, el Pan-cáncer Atlas evidenció similitudes moleculares transtumorales y consolidó el concepto de “genoma teranóstico”. Persisten limitaciones relacionadas con la representatividad poblacional, la heterogeneidad clínica y la aplicabilidad en entornos con recursos limitados. Conclusión: TCGA representó un hito en la oncología de precisión al transformar la comprensión de la biología tumoral y sentar las bases para el desarrollo de terapias dirigidas. Sus datos continúan siendo un recurso central para la investigación oncológica global.
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 72-84
Open AccessEpidemiología molecular: el papel del Atlas del Genoma del Cáncer a lo largo de la historia
Introducción: el Atlas del Genoma del Cáncer (TCGA) ha sido un proyecto colaborativo internacional y multiinstitucional diseñado para caracterizar de manera integral las alteraciones moleculares de tumores de alta relevancia clínica. Este trabajo resume sus principales aportes, así como las limitaciones y retos derivados de su implementación. Métodos: se realizó una búsqueda estructurada en PubMed, EMBASE y Web of Science sobre TCGA, incluyendo publicaciones relacionadas con sus resultados, metodología, limitaciones y repercusiones clínicas y traslacionales. Resultados: se identificaron 88 publicaciones relevantes. TCGA analizó más de 20.000 muestras correspondientes a 33 tipos tumorales, integrando datos genómicos, transcriptómicos, epigenómicos y proteómicos. Entre sus contribuciones más relevantes destacan: a) la redefinición de la clasificación tumoral mediante subtipos moleculares, b) la identificación de mutaciones y vías de señalización con impacto terapéutico, como IDH1 en gliomas y subtipos moleculares en cáncer de mama, endometrio y estómago, c) la validación de biomarcadores pronósticos y predictivos, y d) el desarrollo de bases de datos abiertas que impulsaron estudios traslacionales y ensayos clínicos tipo canasta. En 2018, el Pan-cáncer Atlas evidenció similitudes moleculares transtumorales y consolidó el concepto de “genoma teranóstico”. Persisten limitaciones relacionadas con la representatividad poblacional, la heterogeneidad clínica y la aplicabilidad en entornos con recursos limitados. Conclusión: TCGA representó un hito en la oncología de precisión al transformar la comprensión de la biología tumoral y sentar las bases para el desarrollo de terapias dirigidas. Sus datos continúan siendo un recurso central para la investigación oncológica global.
- Open Access
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 425-449
Relación de la ancestría genética en las alteraciones moleculares en distintos modelos de cáncer
Introducción: las disparidades en cáncer se han atribuido principalmente a determinantes sociales y factores del estilo de vida, sin embargo, evidencia reciente sugiere que la ancestría genética también puede influir en la biología tumoral. Comprender esta relación es clave para avanzar hacia una medicina de precisión más equitativa. Métodos: se realizó una revisión de la literatura mediante PubMed sin restricciones temporales. Se incluyeron estudios originales que evaluaran la asociación entre la ancestría genética, inferida a partir de marcadores genómicos, y alteraciones moleculares en distintos tipos de cáncer, excluyendo aquellos basados únicamente en autoidentificación étnica. Resultados: cuarenta estudios cumplieron los criterios de inclusión. Los cánceres más representados fueron mama, pulmón, colon, próstata y neoplasias hematológicas. En cáncer de mama, la ancestría africana se asoció con mutaciones en TP53 y activación de las vías NFκB y EGFR, mientras que la ancestría europea se asoció con mutaciones en PIK3CA y PTEN. En cáncer de pulmón, la ancestría asiática mostró alta prevalencia de mutaciones en EGFR y fusiones de ALK. En cáncer colorrectal, la ancestría africana se asoció con alteraciones en KRAS y APC, y la europea con BRAF y CHEK2. Además, se identificaron asociaciones específicas en cáncer de próstata y leucemia linfoblástica aguda. Conclusión: la evidencia disponible respalda que la ancestría genética influye en los perfiles moleculares tumorales y puede contribuir a explicar las disparidades en cáncer. Sin embargo, aún persiste una subrepresentación de grupos con alta ancestría nativa americana, como la latinoamericana, lo que limita la equidad en la medicina de precisión.
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 425-449
Open AccessRelación de la ancestría genética en las alteraciones moleculares en distintos modelos de cáncer
Introducción: las disparidades en cáncer se han atribuido principalmente a determinantes sociales y factores del estilo de vida, sin embargo, evidencia reciente sugiere que la ancestría genética también puede influir en la biología tumoral. Comprender esta relación es clave para avanzar hacia una medicina de precisión más equitativa. Métodos: se realizó una revisión de la literatura mediante PubMed sin restricciones temporales. Se incluyeron estudios originales que evaluaran la asociación entre la ancestría genética, inferida a partir de marcadores genómicos, y alteraciones moleculares en distintos tipos de cáncer, excluyendo aquellos basados únicamente en autoidentificación étnica. Resultados: cuarenta estudios cumplieron los criterios de inclusión. Los cánceres más representados fueron mama, pulmón, colon, próstata y neoplasias hematológicas. En cáncer de mama, la ancestría africana se asoció con mutaciones en TP53 y activación de las vías NFκB y EGFR, mientras que la ancestría europea se asoció con mutaciones en PIK3CA y PTEN. En cáncer de pulmón, la ancestría asiática mostró alta prevalencia de mutaciones en EGFR y fusiones de ALK. En cáncer colorrectal, la ancestría africana se asoció con alteraciones en KRAS y APC, y la europea con BRAF y CHEK2. Además, se identificaron asociaciones específicas en cáncer de próstata y leucemia linfoblástica aguda. Conclusión: la evidencia disponible respalda que la ancestría genética influye en los perfiles moleculares tumorales y puede contribuir a explicar las disparidades en cáncer. Sin embargo, aún persiste una subrepresentación de grupos con alta ancestría nativa americana, como la latinoamericana, lo que limita la equidad en la medicina de precisión.
- Open Access
- 27 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0306037
Genetic ancestry is related to potential sources of breast cancer health disparities among Colombian women
Breast cancer health disparities are linked to clinical-pathological determinants, socioeconomic inequities, and biological factors such as genetic ancestry. These factors collectively interact in complex ways, influencing disease behavior, especially among highly admixed populations like Colombians. In this study, we assessed contributing factors to breast cancer health disparities according to genetic ancestry in Colombian patients from a national cancer reference center. We collected non-tumoral paraffin embedded (FFPE) blocks from 361 women diagnosed with breast cancer at the National Cancer Institute (NCI) to estimate genetic ancestry using a 106-ancestry informative marker (AIM) panel. Differences in European, Indigenous American (IA) and African ancestry fractions were analyzed according to potential sources of breast cancer health disparities, like etiology, tumor-biology, treatment administration, and socioeconomic-related factors using a Kruskal–Wallis test. Our analysis revealed a significantly higher IA ancestry among overweight patients with larger tumors and those covered by a subsidized health insurance. Conversely, we found a significantly higher European ancestry among patients with smaller tumors, residing in middle-income households, and affiliated to the contributory health regime, whereas a higher median of African ancestry was observed among patients with either a clinical, pathological, or stable response to neoadjuvant treatment. Altogether, our results suggest that the genetic legacy among Colombian patients, measured as genetic ancestry fractions, may be reflected in many of the clinical-pathological variables and socioeconomic factors that end up contributing to health disparities for this disease.
- 27 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0306037
Open AccessGenetic ancestry is related to potential sources of breast cancer health disparities among Colombian women
Breast cancer health disparities are linked to clinical-pathological determinants, socioeconomic inequities, and biological factors such as genetic ancestry. These factors collectively interact in complex ways, influencing disease behavior, especially among highly admixed populations like Colombians. In this study, we assessed contributing factors to breast cancer health disparities according to genetic ancestry in Colombian patients from a national cancer reference center. We collected non-tumoral paraffin embedded (FFPE) blocks from 361 women diagnosed with breast cancer at the National Cancer Institute (NCI) to estimate genetic ancestry using a 106-ancestry informative marker (AIM) panel. Differences in European, Indigenous American (IA) and African ancestry fractions were analyzed according to potential sources of breast cancer health disparities, like etiology, tumor-biology, treatment administration, and socioeconomic-related factors using a Kruskal–Wallis test. Our analysis revealed a significantly higher IA ancestry among overweight patients with larger tumors and those covered by a subsidized health insurance. Conversely, we found a significantly higher European ancestry among patients with smaller tumors, residing in middle-income households, and affiliated to the contributory health regime, whereas a higher median of African ancestry was observed among patients with either a clinical, pathological, or stable response to neoadjuvant treatment. Altogether, our results suggest that the genetic legacy among Colombian patients, measured as genetic ancestry fractions, may be reflected in many of the clinical-pathological variables and socioeconomic factors that end up contributing to health disparities for this disease.
- Open Access
- 19 July 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (7) , 1148
Validation of an Ultraviolet Light Response Gene Signature for Predicting Prognosis in Patients with Uveal Melanoma
Uveal melanoma (UVM) is a highly aggressive ocular cancer with limited therapeutic options and poor prognosis particularly for patients with liver metastasis. As such, the identification of new prognostic biomarkers is critical for developing effective treatment strategies. In this study, we aimed to investigate the potential of an ultraviolet light response gene signature to predict the prognosis of UVM patients. Our approach involved the development of a prognostic model based on genes associated with the cellular response to UV light. By employing this model, we generated risk scores to stratify patients into high- and low-risk groups. Furthermore, we conducted differential expression analysis between these two groups and explored the estimation of immune infiltration. To validate our findings, we applied our methodology to an independent UVM cohort. Through our study, we introduced a novel survival prediction tool and shed light on the underlying cellular processes within UVM tumors, emphasizing the involvement of immune subsets in tumor progression.
- 19 July 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (7) , 1148
Open AccessValidation of an Ultraviolet Light Response Gene Signature for Predicting Prognosis in Patients with Uveal Melanoma
Uveal melanoma (UVM) is a highly aggressive ocular cancer with limited therapeutic options and poor prognosis particularly for patients with liver metastasis. As such, the identification of new prognostic biomarkers is critical for developing effective treatment strategies. In this study, we aimed to investigate the potential of an ultraviolet light response gene signature to predict the prognosis of UVM patients. Our approach involved the development of a prognostic model based on genes associated with the cellular response to UV light. By employing this model, we generated risk scores to stratify patients into high- and low-risk groups. Furthermore, we conducted differential expression analysis between these two groups and explored the estimation of immune infiltration. To validate our findings, we applied our methodology to an independent UVM cohort. Through our study, we introduced a novel survival prediction tool and shed light on the underlying cellular processes within UVM tumors, emphasizing the involvement of immune subsets in tumor progression.
- Open Access
- 30 March 2023
- Published by Instituto Nacional de Cancerologia in Revista Colombiana de Cancerología
- Vol. 27 (1) , 80-90
Análisis de la coexpresión de HER2/GRB7 y su asociación con variables clinicopatológicas en un grupo de mujeres colombianas con diagnóstico de cáncer de mama invasivo
Objetivo. Analizar las diferencias en la presentación de variables clínico-patológicas, de acuerdo con la expresión proteica de GRB7, en tumores HER2 positivos en mujeres colombianas con cáncer de mama invasivo, diagnosticado entre los años 2013 y 2015 en el Instituto Nacional de Cancerología E.S.E (INC). Métodos. Se incluyeron 158 pacientes con diagnóstico confirmado de cáncer de mama ductal invasivo. Se evaluó la expresión de los receptores hormonales (receptor de estrógeno (RE) y de progesterona (RP)), HER2, Ki67 y GRB7, mediante inmunohistoquímica (IHQ), y a partir de estos, se clasificaron los tumores en subtipos intrínsecos. Los análisis estadísticos incluyeron las pruebas de Chi-cuadrado/test exacto de Fisher para las variables categóricas, y la prueba U Mann Whitney/ Kruskal Wallis para las variables cuantitativas. Se evaluó la supervivencia global (SG) y libre de enfermedad (SLR) según la coexpresión de HER2/GRB7 usando el método de Kaplan-Meier y el test de log-rank. Resultados. La expresión de GRB7 se observó exclusivamente en tumores HER2-positivos (luminal B/HER2+ y HER2-enriquecidos: p<0,001). Los casos HER2+/GRB7+ mostraron una mayor expresión de Ki67 (40% vs. 27,5%, p=0,029), pero una tendencia a presentar un menor tamaño tumoral (30 mm vs. 51 mm, p=0,097), comparado con los tumores HER2+/GRB7-. No obstante, no se observaron diferencias en la supervivencia según la coexpresión de HER2/GRB7 (SG: p=0,6; SLR: p=0,07). Conclusiones. En nuestra muestra de estudio, la expresión de GRB7 en tumores HER2+ no se asoció con características clínico-patológicas de pronóstico desfavorable.
- 30 March 2023
- Published by Instituto Nacional de Cancerologia in Revista Colombiana de Cancerología
- Vol. 27 (1) , 80-90
Open AccessAnálisis de la coexpresión de HER2/GRB7 y su asociación con variables clinicopatológicas en un grupo de mujeres colombianas con diagnóstico de cáncer de mama invasivo
Objetivo. Analizar las diferencias en la presentación de variables clínico-patológicas, de acuerdo con la expresión proteica de GRB7, en tumores HER2 positivos en mujeres colombianas con cáncer de mama invasivo, diagnosticado entre los años 2013 y 2015 en el Instituto Nacional de Cancerología E.S.E (INC). Métodos. Se incluyeron 158 pacientes con diagnóstico confirmado de cáncer de mama ductal invasivo. Se evaluó la expresión de los receptores hormonales (receptor de estrógeno (RE) y de progesterona (RP)), HER2, Ki67 y GRB7, mediante inmunohistoquímica (IHQ), y a partir de estos, se clasificaron los tumores en subtipos intrínsecos. Los análisis estadísticos incluyeron las pruebas de Chi-cuadrado/test exacto de Fisher para las variables categóricas, y la prueba U Mann Whitney/ Kruskal Wallis para las variables cuantitativas. Se evaluó la supervivencia global (SG) y libre de enfermedad (SLR) según la coexpresión de HER2/GRB7 usando el método de Kaplan-Meier y el test de log-rank. Resultados. La expresión de GRB7 se observó exclusivamente en tumores HER2-positivos (luminal B/HER2+ y HER2-enriquecidos: p<0,001). Los casos HER2+/GRB7+ mostraron una mayor expresión de Ki67 (40% vs. 27,5%, p=0,029), pero una tendencia a presentar un menor tamaño tumoral (30 mm vs. 51 mm, p=0,097), comparado con los tumores HER2+/GRB7-. No obstante, no se observaron diferencias en la supervivencia según la coexpresión de HER2/GRB7 (SG: p=0,6; SLR: p=0,07). Conclusiones. En nuestra muestra de estudio, la expresión de GRB7 en tumores HER2+ no se asoció con características clínico-patológicas de pronóstico desfavorable.
- Open Access
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 989761
Association of genetic ancestry with HER2, GRB7 AND estrogen receptor expression among Colombian women with breast cancer
Background: Our previous study reported higher mRNA levels of the human epidermal growth factor receptor 2 (HER2)-amplicon genes ERBB2 and GRB7 in estrogen receptor (ER)-positive breast cancer patients with relatively high Indigenous American (IA) ancestry from Colombia. Even though the protein expression of HER2 and GRB7 is highly correlated, they may also express independently, an event that could change the patients’ prognosis. In this study, we aimed to explore the differences in ER, HER2 and GRB7 protein expression according to genetic ancestry, to further assess the clinical implications of this association.Methods: We estimated genetic ancestry from non-tumoral breast tissue DNA and assessed tumoral protein expression of ER, HER2, and GRB7 by immunohistochemistry in a cohort of Colombian patients from different health institutions. We used binomial and multinomial logistic regression models to test the association between genetic ancestry and protein expression. Kaplan-Meier and log-rank tests were used to evaluate the effect of HER2/GRB7 co-expression on patients’ survival.Results: Our results show that patients with higher IA ancestry have higher odds of having HER2+/GRB7- breast tumors, compared to the HER2-/GRB7- subtype, and this association seems to be stronger among ER-positive tumors (ER+/HER2+/GRB7-: OR=3.04, 95% CI, 1.47-6.37, p<0.05). However, in the multivariate model this association was attenuated (OR=1.80, 95% CI, 0.72-4.44, p=0.19). On the other hand, it was observed that having a higher European ancestry patients presented lower odds of ER+/HER2+/GRB7- breast tumors, this association remained significant in the multivariate model (OR=0.36, 95% CI, 0.13 - 0.93, p= 0.0395). The survival analysis according to HER2/GRB7 co-expression did not show statistically significant differences in the overall survival and recurrence-free survival.Conclusions: Our results suggest that Colombian patients with higher IA ancestry and a lower European fraction have higher odds of ER+/HER2+/GRB7- tumors compared to ER+/HER2-/GRB7- disease. However, this association does not seem to be associated with patients’ overall or recurrence-free survival.
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 989761
Open AccessAssociation of genetic ancestry with HER2, GRB7 AND estrogen receptor expression among Colombian women with breast cancer
Background: Our previous study reported higher mRNA levels of the human epidermal growth factor receptor 2 (HER2)-amplicon genes ERBB2 and GRB7 in estrogen receptor (ER)-positive breast cancer patients with relatively high Indigenous American (IA) ancestry from Colombia. Even though the protein expression of HER2 and GRB7 is highly correlated, they may also express independently, an event that could change the patients’ prognosis. In this study, we aimed to explore the differences in ER, HER2 and GRB7 protein expression according to genetic ancestry, to further assess the clinical implications of this association.Methods: We estimated genetic ancestry from non-tumoral breast tissue DNA and assessed tumoral protein expression of ER, HER2, and GRB7 by immunohistochemistry in a cohort of Colombian patients from different health institutions. We used binomial and multinomial logistic regression models to test the association between genetic ancestry and protein expression. Kaplan-Meier and log-rank tests were used to evaluate the effect of HER2/GRB7 co-expression on patients’ survival.Results: Our results show that patients with higher IA ancestry have higher odds of having HER2+/GRB7- breast tumors, compared to the HER2-/GRB7- subtype, and this association seems to be stronger among ER-positive tumors (ER+/HER2+/GRB7-: OR=3.04, 95% CI, 1.47-6.37, p<0.05). However, in the multivariate model this association was attenuated (OR=1.80, 95% CI, 0.72-4.44, p=0.19). On the other hand, it was observed that having a higher European ancestry patients presented lower odds of ER+/HER2+/GRB7- breast tumors, this association remained significant in the multivariate model (OR=0.36, 95% CI, 0.13 - 0.93, p= 0.0395). The survival analysis according to HER2/GRB7 co-expression did not show statistically significant differences in the overall survival and recurrence-free survival.Conclusions: Our results suggest that Colombian patients with higher IA ancestry and a lower European fraction have higher odds of ER+/HER2+/GRB7- tumors compared to ER+/HER2-/GRB7- disease. However, this association does not seem to be associated with patients’ overall or recurrence-free survival.
- Open Access
- 3 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4306-4320
Metabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer
Background: The role of ERG‐status molecular subtyping in prognosis of prostate cancer (PCa) is still under debate. In this study, we identified differentially expressed genes (DEGs) according to ERG‐status to explore their enriched pathways and implications in prognosis in Hispanic/Latino PCa patients.Methods: RNA from 78 Hispanic PCa tissues from radical prostatectomies (RP) were used for RNA‐sequencing. ERGhigh/ERGlow tumor groups were determined based on the 1.5‐fold change median expression in non‐tumor samples. DEGs with a False Discovery Rate (FDR) < 0.01 and a fold change >2 were identified between ERGhigh and ERGlow tumors and submitted to enrichment analysis in MetaCore. Survival and association analyses were performed to evaluate biochemical recurrence (BCR)‐free survival.Results: The identification of 150 DEGs between ERGhigh and ERGlow tumors revealed clustering of most of the non‐BCR cases (60%) into de ERGhigh group and most of the BCR cases (60.8%) in ERGlow group. Kaplan–Meier survival curves showed a worst BCR‐free survival for ERGlow patients, and a significant reduced risk of BCR was observed for ERGhigh cases (OR = 0.29 (95%CI, 0.10–0.8)). Enrichment pathway analysis identified metabolic‐related pathways, such as the renin‐angiotensin system and angiotensin maturation system, the linoleic acid metabolism, and polyamines metabolism in these ERG groups.Conclusions: ERGlow tumor cases were associated with poor BCR‐free survival in our Hispanic/Latino patients, with metabolism‐related pathways altered in the BCR progression.Impact: Our findings suggest the need to dissect the role of diet, metabolism, and lifestyle as risk factors for more aggressive PCa subtypes.
- 3 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4306-4320
Open AccessMetabolic pathways enriched according to ERG status are associated with biochemical recurrence in Hispanic/Latino patients with prostate cancer
Background: The role of ERG‐status molecular subtyping in prognosis of prostate cancer (PCa) is still under debate. In this study, we identified differentially expressed genes (DEGs) according to ERG‐status to explore their enriched pathways and implications in prognosis in Hispanic/Latino PCa patients.Methods: RNA from 78 Hispanic PCa tissues from radical prostatectomies (RP) were used for RNA‐sequencing. ERGhigh/ERGlow tumor groups were determined based on the 1.5‐fold change median expression in non‐tumor samples. DEGs with a False Discovery Rate (FDR) < 0.01 and a fold change >2 were identified between ERGhigh and ERGlow tumors and submitted to enrichment analysis in MetaCore. Survival and association analyses were performed to evaluate biochemical recurrence (BCR)‐free survival.Results: The identification of 150 DEGs between ERGhigh and ERGlow tumors revealed clustering of most of the non‐BCR cases (60%) into de ERGhigh group and most of the BCR cases (60.8%) in ERGlow group. Kaplan–Meier survival curves showed a worst BCR‐free survival for ERGlow patients, and a significant reduced risk of BCR was observed for ERGhigh cases (OR = 0.29 (95%CI, 0.10–0.8)). Enrichment pathway analysis identified metabolic‐related pathways, such as the renin‐angiotensin system and angiotensin maturation system, the linoleic acid metabolism, and polyamines metabolism in these ERG groups.Conclusions: ERGlow tumor cases were associated with poor BCR‐free survival in our Hispanic/Latino patients, with metabolism‐related pathways altered in the BCR progression.Impact: Our findings suggest the need to dissect the role of diet, metabolism, and lifestyle as risk factors for more aggressive PCa subtypes.
- Open Access
- 18 July 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 910976
Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) occurs more frequently in young (<50 years) non-Hispanic black and Hispanic/Latina women. It is considered the most aggressive subtype of breast cancer, although, recently, immune infiltrate has been associated with long-term survival, lower risk of death and recurrence, and response to neoadjuvant chemotherapy. The aim of this review was to evaluate the clinical impact of the immune infiltrate in TNBC by discussing whether its prognostic value varies across different populations. A comprehensive systematic search in databases such as PubMed and Web of Science was conducted to include papers focused on tumor-infiltrating lymphocytes (TILs) in TNBC in different population groups and that were published before January 2021. TNBC patients with higher levels of TILs had longer overall survival and disease-free survival times compared with TNBC patients with low TIL levels. Similar results were observed for CD4+, CD8+ TIL populations. On the other hand, patients with high TIL levels showed a higher rate of pathological complete response regardless of the population group (Asian, European, and American). These results altogether suggest that TIL subpopulations might have a prognostic role in TNBC, but the underlying mechanism needs to be elucidated. Although the prognosis value of TILs was not found different between the population groups analyzed in the revised literature, further studies including underrepresented populations with different genetic ancestries are still necessary to conclude in this regard.
- 18 July 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 910976
Open AccessImmune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) occurs more frequently in young (<50 years) non-Hispanic black and Hispanic/Latina women. It is considered the most aggressive subtype of breast cancer, although, recently, immune infiltrate has been associated with long-term survival, lower risk of death and recurrence, and response to neoadjuvant chemotherapy. The aim of this review was to evaluate the clinical impact of the immune infiltrate in TNBC by discussing whether its prognostic value varies across different populations. A comprehensive systematic search in databases such as PubMed and Web of Science was conducted to include papers focused on tumor-infiltrating lymphocytes (TILs) in TNBC in different population groups and that were published before January 2021. TNBC patients with higher levels of TILs had longer overall survival and disease-free survival times compared with TNBC patients with low TIL levels. Similar results were observed for CD4+, CD8+ TIL populations. On the other hand, patients with high TIL levels showed a higher rate of pathological complete response regardless of the population group (Asian, European, and American). These results altogether suggest that TIL subpopulations might have a prognostic role in TNBC, but the underlying mechanism needs to be elucidated. Although the prognosis value of TILs was not found different between the population groups analyzed in the revised literature, further studies including underrepresented populations with different genetic ancestries are still necessary to conclude in this regard.
- Open Access
- 18 July 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Effect of neoadjuvant therapy on breast cancer biomarker profile
Background: Breast cancer clinical management requires the assessment of hormone receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor receptor 2 (HER2) and cellular proliferation index Ki67, by immunohistochemistry (IHC), in order to choose and guide therapy according to tumor biology. Many studies have reported contradictory results regarding changes in the biomarker profile after neoadjuvant therapy (NAT). Given its clinical implications for the disease management, we aimed to analyze changes in ER, PR, HER2, and Ki67 expression in paired core-needle biopsies and surgical samples in breast cancer patients that had either been treated or not with NAT.Methods: We included 139 patients with confirmed diagnosis of invasive ductal breast carcinoma from the Colombian National Cancer Institute. Variation in biomarker profile were assessed according to NAT administration (NAT and no-NAT treated cases) and NAT scheme (hormonal, cytotoxic, cytotoxic + trastuzumab, combined). Chi-squared and Wilcoxon signed-rank test were used to identify changes in biomarker status and percentage expression, respectively, in the corresponding groups.Results: We did not find any significant variations in biomarker status or expression values in the no-NAT group. In cases previously treated with NAT, we did find a statistically significant decrease in Ki67 (p < 0.001)and PR (p = 0.02605) expression. When changes were evaluated according to NAT scheme, we found a significant decrease in both Ki67 status (p = 0.02977) and its expression values (p < 0.001) in cases that received the cytotoxic treatment.Conclusions: Our results suggest that PR and Ki67 expression can be altered by NAT administration, whereas cases not previously treated with NAT do not present IHC biomarker profile variations. The re-evaluation of these two biomarkers after NAT could provide valuable information regarding treatment response and prognosis for breast cancer patients.
- 18 July 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Open AccessEffect of neoadjuvant therapy on breast cancer biomarker profile
Background: Breast cancer clinical management requires the assessment of hormone receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor receptor 2 (HER2) and cellular proliferation index Ki67, by immunohistochemistry (IHC), in order to choose and guide therapy according to tumor biology. Many studies have reported contradictory results regarding changes in the biomarker profile after neoadjuvant therapy (NAT). Given its clinical implications for the disease management, we aimed to analyze changes in ER, PR, HER2, and Ki67 expression in paired core-needle biopsies and surgical samples in breast cancer patients that had either been treated or not with NAT.Methods: We included 139 patients with confirmed diagnosis of invasive ductal breast carcinoma from the Colombian National Cancer Institute. Variation in biomarker profile were assessed according to NAT administration (NAT and no-NAT treated cases) and NAT scheme (hormonal, cytotoxic, cytotoxic + trastuzumab, combined). Chi-squared and Wilcoxon signed-rank test were used to identify changes in biomarker status and percentage expression, respectively, in the corresponding groups.Results: We did not find any significant variations in biomarker status or expression values in the no-NAT group. In cases previously treated with NAT, we did find a statistically significant decrease in Ki67 (p < 0.001)and PR (p = 0.02605) expression. When changes were evaluated according to NAT scheme, we found a significant decrease in both Ki67 status (p = 0.02977) and its expression values (p < 0.001) in cases that received the cytotoxic treatment.Conclusions: Our results suggest that PR and Ki67 expression can be altered by NAT administration, whereas cases not previously treated with NAT do not present IHC biomarker profile variations. The re-evaluation of these two biomarkers after NAT could provide valuable information regarding treatment response and prognosis for breast cancer patients.